DNA polymerase beta2
a DNA polymerase beta-related enzyme that contains BRCA1 COOH terminus (BRCT) motif that is dispensable for its polymerase activity; amino acid sequence in first source; GenBank AF283478
Also Known As:
DNA polymerase beta 2; DNA polymerase lambda; DNA polymerase, Pol lambda; POLL protein; Pol beta2
Networked: 6
relevant articles (0 outcomes,
0 trials/studies)
Bio-Agent Context: Research Results
Experts
1. | Hübscher, Ulrich:
1 article
(11/2017)
|
2. | Maga, Giovanni:
1 article
(11/2017)
|
3. | van Loon, Barbara:
1 article
(11/2017)
|
4. | Bush, Korie B:
1 article
(11/2016)
|
5. | Nemec, Antonia A:
1 article
(11/2016)
|
6. | Schulz, Vincent:
1 article
(11/2016)
|
7. | Sweasy, Joann B:
1 article
(11/2016)
|
8. | Taylor, B Frazier:
1 article
(11/2016)
|
9. | Towle-Weicksel, Jamie B:
1 article
(11/2016)
|
10. | Tuck, David P:
1 article
(11/2016)
|
Related Diseases
1. | Chromosomal Instability (Chromosome Stability)
|
2. | Genomic Instability
|
3. | Ankylosing Spondylitis
03/05/2015
- " 71 potential targets of dioscin from humans, 7 from rats and 8 from mice were screened, and the prediction results showed that the most likely targets of dioscin were cyclin A2, calmodulin, hemoglobin subunit beta, DNA topoisomerase I, DNA polymerase lambda, nitric oxide synthase and UDP-N-acetylhexosamine pyrophosphorylase, etc. Many diseases including experimental autoimmune encephalomyelitis of human, temporal lobe epilepsy of rat and ankylosing spondylitis of mouse, may be inhibited by dioscin through regulating immune response alternative complement pathway, G-protein signaling RhoB regulation pathway and immune response antiviral actions of interferons, etc. The most relevant networks (5 from human, 3 from rat and 5 from mouse) indicated that dioscin may be a TOP1 inhibitor, which can treat cancer though the cell cycle- transition and termination of DNA replication pathway. "
|
4. | Situs Inversus
|
5. | Sinusitis
|
|
Related Drugs and Biologics